Current and future therapies for invasive aspergillosis

Publication date: June 2015 Source:Pulmonary Pharmacology & Therapeutics, Volume 32 Author(s): Matteo Bassetti , Davide Pecori , Paola Della Siega , Silvia Corcione , Francesco Giuseppe De Rosa Invasive fungal infections have increase worldwide and represent a threat for immunocompromised patients including HIV-infected, recipients of solid organ and stem cell transplants, and patients receiving immunosuppressive therapies. High mortality rates and difficulties in early diagnosis characterize pulmonary fungal infections. Invasive pulmonary aspergillosis has been reviewed focussing on therapeutic management. Although new compounds have become available in the past years (i.e., amphotericin B lipid formulations, last-generation azoles, and echinocandines), new diagnostic tools and careful therapeutic management are mandatory to assure an early appropriate targeted treatment that represents the key factor for a successful conservative approach in respiratory fungal infections.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research